View : 21 Download: 0

Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia

Title
Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia
Authors
Hong K.P.Byun Y.J.Yoon H.Park Y.Y.Chung W.S.
Ewha Authors
박영요정우식윤하나변영준
SCOPUS Author ID
박영요scopus; 정우식scopus; 윤하나scopus
Issue Date
2010
Journal Title
Korean Journal of Urology
ISSN
2005-6737JCR Link
Citation
vol. 51, no. 7, pp. 488 - 491
Indexed
SCOPUS; KCI scopus
Abstract
Purpose: We aimed to determine the treatment of choice criteria for benign prostatic hyperplasia (BPH) by analyzing the factors causing alpha-adrenergic receptor blocker (α-blocker) monotherapy failure. Materials and Methods: This retrospective study enrolled 129 patients with BPH who were prescribed an α-blocker. Patients were allocated to a transurethral resection of prostate (TURP) group (after having at least a 6-month duration of medication) and an α-blocker group. We compared the differences between the two groups for their initial prostate volume, serum prostate-specific antigen (PSA), maximum urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and postvoid residual urine volume (PVR). Results: Of the 129 patients, 54 were in the TURP group and 75 were in the α-blocker group. Statistically significant differences (p<0.05) between the two groups were found in the prostate volume (50.8 ml vs. 34.4 ml), PSA (6.8 ng/ml vs. 3.6 ng/ml), Qmax (6.84 ml/sec vs. 9.99 ml/sec), and IPSS (27.3 vs. 16.8). According to the multiple regression analysis, the significant factors in ?-blocker monotherapy failure were the IPSS (p <0.001) and prostate volume (p=0.015). According to the receiver operating characteristic (ROC) curve-based prediction regarding surgical treatment, the best cutoff value for the prostate volume and IPSS were 35.65 ml (sensitivity 0.722, specificity 0.667) and 23.5 (sensitivity 0.852, specificity 0.840), respectively. Conclusions: At the initial diagnosis of BPH, patients with a larger prostate volume and severe IPSS have a higher risk of ?-blocker monotherapy failure. In this case, combined therapy with 5-alpha-reductase inhibitor (5-ARI) or surgical treatment may be useful. © The Korean Urological Association, 2010.
DOI
10.4111/kju.2010.51.7.488
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE